ArticleOdontology2026
Salivary gland function and redox status in young adult male rats treated with the psychostimulant short-release methylphenidate.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study evaluated the salivary flow rate, biochemical composition of saliva, and redox status of the salivary glands in rats treated with short-release methylphenidate hydrochloride (MPH), a psychostimulant commonly used in the treatment of attention deficit hyperactivity disorder. Twenty young adult male Wistar rats (6 weeks old) were randomly assigned to two groups (n = 10): Control (0.9% saline) and MPH (3 mg/kg). After 28 consecutive days of intragastric gavage, saliva was collected following pilocarpine stimulation, for analysis of salivary flow rate (mL/min/g of salivary gland), pH, buffering capacity, and biochemical composition. Redox status markers were also assessed in the parotid and submandibular glands. The results showed that MPH treatment reduced salivary flow rate and buffering capacity without altering pH. Increases in total protein concentration, amylase activity, and concentrations of calcium and phosphate were observed, with no significant differences in sodium, potassium, or chloride content. MPH also decreased total oxidant capacity and the activities of superoxide dismutase and catalase in both salivary glands. Interestingly, oxidative damage to lipids and proteins was lower in the MPH group for the parotid glands. On the other hand, MPH reduced total antioxidant capacity and glutathione peroxidase activity in the submandibular glands, while it did not alter uric acid and reduced glutathione concentrations in either gland. In summary, MPH reduced salivary flow, altered the salivary biochemical composition, and disrupted redox homeostasis in the salivary glands. These salivary biochemical alterations may corroborate the reduction in salivary flow and contribute to oral health deterioration associated with methylphenidate use.
Indexed as
Identifiers
41198998What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.